mAbxience EN2026-09-25T10:51:40+02:00

BIOPHARMACEUTICAL DEVELOPMENT

Biologics expertise

Built to support innovation

We are a leading vertically integrated biopharmaceutical company committed to improving patient access to treatments worldwide. Our strong in-house R&D capabilities set us apart in the development of biosimilars and innovator biologics

CDMO PLATFORM

End-to-end solutions to meet any manufacturing need

Thanks to our own development and manufacturing CDMO platform, we provide integrated services adapted to your requirements: from research batches to commercial batches, big or small. We have 15+ of experience in the development and commercialization of biopharmaceuticals.

JOIN US!

Do you want to work at mAbxience?

WHAT’S NEW?

Catch up with our latest developments

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

mAbxience and Amneal Announce FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Go to Top